Article
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
The Lancet. Oncology - 1 Nov 2021
DiNardo Courtney D, Schuh Andre C, Stein Eytan M, Montesinos Pau, Wei Andrew H, de Botton Stéphane, Zeidan Amer M, Fathi Amir T, Kantarjian Hagop M, Bennett John M, Frattini Mark G, Martin-Regueira Patricia, Lersch Frederik, Gong Jing, Hasan Maroof, Vyas Paresh, Döhner Hartmut
Abstract excerpt
BACKGROUND: Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2) proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia ineligible for intensive chemotherapy. METHODS: This open-label, phase 1b/2 trial was done at 43 clinical sites in 12 countries (the USA, Germany, Canada,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.